TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01447706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard dosing Paclitaxel (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard dosing Paclitaxel (IV)
Study: NCT01202188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indacaterol (QAB149)
Description: Capsules for inhalation delivered via SDDPI.
Study: NCT02198300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty with stent implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty with stent implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antipletlet therapy (DAPT)
Description: DAPT given to each patient before stent implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antipletlet therapy (DAPT)
Description: DAPT given to each patient before stent implantation
Study: NCT01084941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention group
Description: Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
Study: NCT03594058

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study: NCT00002825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT01202188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Capsules for inhalation delivered via HandiHaler® device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match capsules for inhalation delivered via SDDPI.
Study: NCT01324050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered psychodynamic therapy for depression
Description: This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
Study: NCT02885753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU continuous
Description: 2400 mg/m² intravenously over 46 hours
Study: NCT01324050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered therapist support
Description: This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
Study: NCT02885753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m² intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m² intravenous
Study: NCT03937310

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing of swabs collected during surgery
Description: Traditional swabs for culturing as well as swabs for NGS testing will be collected

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing of swabs collected during surgery
Description: Traditional swabs for culturing as well as swabs for NGS testing will be collected
Study: NCT03767530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mibo Thermoflo
Description: Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm compresses and eyelid massage
Description: Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
Study: NCT00281255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study: NCT03369340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Study: NCT00281255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dobutamine
Study: NCT01121822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular
Study: NCT02584673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.
Description: The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
Study: NCT02097576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline mixed with Manuka Honey
Description: Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed Saline Sinus Rinse
Description: Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
Study: NCT05295511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Team Handball programme
Description: All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
Study: NCT03369340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Study: NCT01430949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation of Paroxysmal Atrial Fibrillation
Description: Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
Study: NCT02100813

Intervention type: DRUG
Group type: OTHER
Intervention: LEO 43204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 43204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 43204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03525821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: intranasal use of ketamine 1mg/kg with nitrous oxide
Study: NCT00103779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40 (anti-huCD40 mAb)
Description: 1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
Study: NCT05295511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Team Handball programme
Description: All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Team Handball programme
Description: All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
Study: NCT00648544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Single-dose 80 mg oral immediate-release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Single-dose 80 mg oral immediate-release tablets
Study: NCT04522362

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control task and Trier Social Stress Task
Description: Same as Arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control task and Trier Social Stress Task
Description: Same as Arm
Study: NCT02322034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
Study: NCT02283697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.

Intervention type: OTHER
Group type: OTHER
Intervention: Control: Standard Care
Description: a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
Study: NCT02390895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic repair of myelomeningocele before 26 SA
Description: prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
Study: NCT00208091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin, type B
Description: Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
Study: NCT02057406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2:1 EPA/DHA
Description: 400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High EPA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02799511

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: protein expression
Description: Differential protein expression between the period of acute cerebral ischemia and the control period
Study: NCT02330640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
Study: NCT04187014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminocaproic Acid 1000Mg Tab
Description: Oral administration of a total 6 g of aminocaproic acid to reduce blood loss

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid tablets
Description: Oral administration of 3.9 g of tranexamic acid to reduce blood loss
Study: NCT05609149

Intervention type: PROCEDURE
Intervention: total mesorectal excision
Description: patients must underwent total mesorectal excision
Study: NCT00889460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
Study: NCT01223001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Study: NCT03769454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP-001
Description: PP-001 eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP-001
Description: PP-001 eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP-001
Description: PP-001 eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP-001
Description: PP-001 eye drops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study: NCT04049396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 24 Patient consumed 6,25 g/day Berberine for 6 weeks
Study: NCT02330640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
Study: NCT02627391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Surgical aortic valve replacement
Study: NCT01584752

Intervention type: PROCEDURE
Intervention: Gore-BioA Fistula Plug
Description: Gore-BioA Fistula Plug
Study: NCT02586272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daifert

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Group
Study: NCT03345095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: Intravenous administration of Marizomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral Administration of Temozolomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Oral Administration of Temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 60 Gy in 30 fractions over 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: 60 Gy in 30 fractions over 6 weeks
Study: NCT04015505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'
Description: The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
Study: NCT02330640

Intervention type: DRUG
Group type: OTHER
Intervention: asprin
Description: All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
Study: NCT01829672

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography investigation
Description: 1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration
Study: NCT04365556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASC Intervention
Description: All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
Study: NCT01836445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up!

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Knowledge Control
Study: NCT03232502

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Basic pharmacogenetic panel
Study: NCT03659695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: 69 g/d freeze dried grape powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 69 g/d placebo powder matched for taste and appearance
Study: NCT01657253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-148
Description: Instill 1 drop in each eye four times a day, for 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Instill 1 drop in each eye four times a day, for 60 days